Search Results - "Hettle R"

CO172 Indirect Treatment Comparison of Efficacy and Safety of Capivasertib-Fulvestrant Versus Alpelisib-Fulvestrant for PIK3CA-Altered, HR-Positive, Advanced Breast Cancer after Disease Progression Following Endocrine-Based Therapy.

Authors: de Wilt, E. Hettle, R. Liljas, B.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS49-S50. 2p.

EE315 Building an Open-Source Semi-Markov State Transition Model for Use in Economic Evaluations of Early-Stage Cancer Treatments.

Authors: Hettle, R Peirce, V Morten, P et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS116-S116. 1p.

PT16 Impact of Data Maturity on the Estimation of the within-Trial Hazard Function: An Example from Metastatic Castration Resistant Prostate Cancer.

Authors: Williams, J. Hettle, R. Haugli-Stephens, T.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS425-S426. 2p.

PCN72 Biomarker Testing to Guide Cost Effective Use of PARPi in Patients with Newly Diagnosed Ovarian Cancer.

Authors: Muston, D. Hettle, R. McLaurin, K. et al.

Source: Value in Health. 2020 Supplement 2, Vol. 23, pS434-S434. 1p.

PCN107 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS (PARPI) IN THE MAINTENANCE TREATMENT OF ADVANCED OVARIAN CANCER.

Authors: Hettle, R. McLaurin, K. Mihai, A. et al.

Source: Value in Health. 2020 Supplement 1, Vol. 23, pS42-S42. 1p.

PP3 - Estimating the Health State Utility of Patients with HER2– gBRCA+ Metastatic Breast Cancer Treated with Olaparib or Chemotherapy Via A Mapping Analysis of Eortc QLQ-C30 Data Collected in the Olympiad Clinical Trial.

Authors: Robson, M Hettle, R Degboe, A et al.

Source: Value in Health. 2018 Supplement 1, Vol. 21, pS12-S12. 1p.

PCN6 - Comparative Efficacy And Safety Of Olaparib 300 Mg Tablets Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients With Platinum-Sensitive Relapsed Germline BRCA-Mutated Ovarian Cancer (PSROC).

Authors: Hettle, R Sackeyfio, A Gill, J et al.

Source: Value in Health. Oct2017, Vol. 20 Issue 9, pA412-A412. 1p.

CP1 - Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How.

Authors: Macaulay, R Hettle, R

Source: Value in Health. Oct2017, Vol. 20 Issue 9, pA403-A404. 1p.

PCN119 - Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective

Authors: Hettle, R Suri, G Mistry, R et al.

Source: Value in Health. Oct2017, Vol. 20 Issue 9, pA433-A433. 1p.

MO1 - Achieving Optimal Fit-To-Survival Data Using Cubic Spline Models: A Case-Study Comparing The Fit of Standard and Cubic Spline Models to Survival Data from the Icon6 Study.

Authors: Hettle, R Sackeyfio, A Suri, G

Source: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA347-A347. 1p.

Generating Health State Utility Values from Fact-Ovarian Data Collected in a Phase Ii Maintenance Study in Platinum Sensitive Recurrent Ovarian Cancer (Study 19): A Comparison of Mapping Algorithms.

Authors: Hettle, R. Borrill, J. Suri, G. et al.

Source: Value in Health. Nov2014, Vol. 17 Issue 7, pA646-A646. 1p.

PND7 Disability Progression in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Who Experience Disease Activity Despite Previous Disease Modifying Therapy

Authors: Hettle, R. Murphy, J. Eckert, B.

Source: Value in Health. pA318-A318. 1p.

HTA92 A Targeted Review of Methods for Effect Modifier (EM) and Prognostic Factor Identification in Population Adjusted Indirect Comparisons (PAICs) in NICE Oncology Submissions.

Authors: Cooper, M. Miranda, M. Hettle, R. et al.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS336-S336. 1p.

PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE.

Authors: McCrea, C. MacDonald, D. Hettle, R. et al.

Source: Value in Health. 2019 Supplement 3, Vol. 22, pS476-S476. 1p.

EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective.

Authors: Parackal, A Ting, E Verhoek, A et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS115-S116. 2p.

MSR150 Assessing the Improved Precision of Extrapolated Survival Estimates When Incorporating Real-World Data in Bayesian M-Spline Models.

Authors: Timmins, I Torabi, F Williams, J et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS467-S467. 1p.

PND47 - Health State Utilities In Patients with Relapsing Remitting Multiple Sclerosis Treated with Cladribine Tablets.

Authors: Wong, SL Pv, Hohnhorst Hettle, R et al.

Source: Value in Health. Oct2017, Vol. 20 Issue 9, pA725-A725. 1p.

PCN5 - Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC).

Authors: Sackeyfio, A Gill, J Hettle, R et al.

Source: Value in Health. Oct2017, Vol. 20 Issue 9, pA412-A412. 1p.

PSY75 - Cost-Effectiveness of Adding Novel or Group 5 Interventions To A Background Regimen For The Treatment of Multidrug-Resistant Tuberculosis In Germany.

Authors: Wirth, D Dass, R Hettle, R

Source: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA588-A588. 1p.

Cost Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis.

Authors: Wolfson, L. Walker, A. Hettle, R. et al.

Source: Value in Health. Nov2014, Vol. 17 Issue 7, pA595-A595. 1p.